179 related articles for article (PubMed ID: 32008159)
21. Targeting Two Antigens Associated with B-ALL with CD19-CD123 Compound Car T Cell Therapy.
Yan LE; Zhang H; Wada M; Fang L; Feng J; Zhang W; Chen Q; Cao Y; Pinz KG; Chen KH; Petrov JC; Chen X; Leung LH; Fan XX; Senzel L; Jiang X; Ma Y; Tse W
Stem Cell Rev Rep; 2020 Apr; 16(2):385-396. PubMed ID: 31970687
[TBL] [Abstract][Full Text] [Related]
22. Construction of a new anti-CD19 chimeric antigen receptor and the anti-leukemia function study of the transduced T cells.
An N; Tao Z; Li S; Xing H; Tang K; Tian Z; Rao Q; Wang M; Wang J
Oncotarget; 2016 Mar; 7(9):10638-49. PubMed ID: 26840021
[TBL] [Abstract][Full Text] [Related]
23. Engineered T cells can fight malignant T cells.
Stauss HJ
Blood; 2015 Aug; 126(8):927-8. PubMed ID: 26294714
[TBL] [Abstract][Full Text] [Related]
24. Eradication of B-ALL using chimeric antigen receptor-expressing T cells targeting the TSLPR oncoprotein.
Qin H; Cho M; Haso W; Zhang L; Tasian SK; Oo HZ; Negri GL; Lin Y; Zou J; Mallon BS; Maude S; Teachey DT; Barrett DM; Orentas RJ; Daugaard M; Sorensen PH; Grupp SA; Fry TJ
Blood; 2015 Jul; 126(5):629-39. PubMed ID: 26041741
[TBL] [Abstract][Full Text] [Related]
25. CAR T cells targeting BAFF-R can overcome CD19 antigen loss in B cell malignancies.
Qin H; Dong Z; Wang X; Cheng WA; Wen F; Xue W; Sun H; Walter M; Wei G; Smith DL; Sun X; Fei F; Xie J; Panagopoulou TI; Chen CW; Song JY; Aldoss I; Kayembe C; Sarno L; Müschen M; Inghirami GG; Forman SJ; Kwak LW
Sci Transl Med; 2019 Sep; 11(511):. PubMed ID: 31554741
[TBL] [Abstract][Full Text] [Related]
26. Enhanced Cancer Immunotherapy by Chimeric Antigen Receptor-Modified T Cells Engineered to Secrete Checkpoint Inhibitors.
Li S; Siriwon N; Zhang X; Yang S; Jin T; He F; Kim YJ; Mac J; Lu Z; Wang S; Han X; Wang P
Clin Cancer Res; 2017 Nov; 23(22):6982-6992. PubMed ID: 28912137
[No Abstract] [Full Text] [Related]
27. Effective Targeting of Multiple B-Cell Maturation Antigen-Expressing Hematological Malignances by Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor T Cells.
Friedman KM; Garrett TE; Evans JW; Horton HM; Latimer HJ; Seidel SL; Horvath CJ; Morgan RA
Hum Gene Ther; 2018 May; 29(5):585-601. PubMed ID: 29641319
[TBL] [Abstract][Full Text] [Related]
28. A Syngeneic Mouse B-Cell Lymphoma Model for Pre-Clinical Evaluation of CD19 CAR T Cells.
Kueberuwa G; Zheng W; Kalaitsidou M; Gilham DE; Hawkins RE
J Vis Exp; 2018 Oct; (140):. PubMed ID: 30394400
[TBL] [Abstract][Full Text] [Related]
29. Long-term in vivo microscopy of CAR T cell dynamics during eradication of CNS lymphoma in mice.
Mulazzani M; Fräßle SP; von Mücke-Heim I; Langer S; Zhou X; Ishikawa-Ankerhold H; Leube J; Zhang W; Dötsch S; Svec M; Rudelius M; Dreyling M; von Bergwelt-Baildon M; Straube A; Buchholz VR; Busch DH; von Baumgarten L
Proc Natl Acad Sci U S A; 2019 Nov; 116(48):24275-24284. PubMed ID: 31712432
[TBL] [Abstract][Full Text] [Related]
30. Chimeric Antigen Receptor (CAR) T Cells: Lessons Learned from Targeting of CD19 in B-Cell Malignancies.
Hay KA; Turtle CJ
Drugs; 2017 Mar; 77(3):237-245. PubMed ID: 28110394
[TBL] [Abstract][Full Text] [Related]
31. Efficiency of CD19 chimeric antigen receptor-modified T cells for treatment of B cell malignancies in phase I clinical trials: a meta-analysis.
Zhang T; Cao L; Xie J; Shi N; Zhang Z; Luo Z; Yue D; Zhang Z; Wang L; Han W; Xu Z; Chen H; Zhang Y
Oncotarget; 2015 Oct; 6(32):33961-71. PubMed ID: 26376680
[TBL] [Abstract][Full Text] [Related]
32. Modeling anti-CD19 CAR T cell therapy in humanized mice with human immunity and autologous leukemia.
Jin CH; Xia J; Rafiq S; Huang X; Hu Z; Zhou X; Brentjens RJ; Yang YG
EBioMedicine; 2019 Jan; 39():173-181. PubMed ID: 30579863
[TBL] [Abstract][Full Text] [Related]
33. Fratricide-resistant CD1a-specific CAR T cells for the treatment of cortical T-cell acute lymphoblastic leukemia.
Sánchez-Martínez D; Baroni ML; Gutierrez-Agüera F; Roca-Ho H; Blanch-Lombarte O; González-García S; Torrebadell M; Junca J; Ramírez-Orellana M; Velasco-Hernández T; Bueno C; Fuster JL; Prado JG; Calvo J; Uzan B; Cools J; Camos M; Pflumio F; Toribio ML; Menéndez P
Blood; 2019 May; 133(21):2291-2304. PubMed ID: 30796021
[TBL] [Abstract][Full Text] [Related]
34. Treatment of patients with relapsed or refractory CD19+ lymphoid disease with T lymphocytes transduced by RV-SFG.CD19.CD28.4-1BBzeta retroviral vector: a unicentre phase I/II clinical trial protocol.
Schubert ML; Schmitt A; Sellner L; Neuber B; Kunz J; Wuchter P; Kunz A; Gern U; Michels B; Hofmann S; Hückelhoven-Krauss A; Kulozik A; Ho AD; Müller-Tidow C; Dreger P; Schmitt M
BMJ Open; 2019 May; 9(5):e026644. PubMed ID: 31110096
[TBL] [Abstract][Full Text] [Related]
35. The novel anti-CD19 chimeric antigen receptors with humanized scFv (single-chain variable fragment) trigger leukemia cell killing.
Qian L; Li D; Ma L; He T; Qi F; Shen J; Lu XA
Cell Immunol; 2016; 304-305():49-54. PubMed ID: 26996927
[TBL] [Abstract][Full Text] [Related]
36. Ex vivo Akt inhibition promotes the generation of potent CD19CAR T cells for adoptive immunotherapy.
Urak R; Walter M; Lim L; Wong CW; Budde LE; Thomas S; Forman SJ; Wang X
J Immunother Cancer; 2017; 5():26. PubMed ID: 28331616
[TBL] [Abstract][Full Text] [Related]
37. Sequential treatment with aT19 cells generates memory CAR-T cells and prolongs the lifespan of Raji-B-NDG mice.
Chen R; Wang M; Liu Q; Wu J; Huang W; Li X; Du B; Xu Q; Duan J; Jiao S; Lee HS; Jung NC; Lee JH; Wang Y; Wang Y
Cancer Lett; 2020 Jan; 469():162-172. PubMed ID: 31634527
[TBL] [Abstract][Full Text] [Related]
38. Identification of Potent CD19 scFv for CAR T Cells through scFv Screening with NK/T-Cell Line.
Kang CH; Kim Y; Lee HK; Lee SM; Jeong HG; Choi SU; Park CH
Int J Mol Sci; 2020 Dec; 21(23):. PubMed ID: 33271901
[TBL] [Abstract][Full Text] [Related]
39. A Tet-On Inducible System for Controlling CD19-Chimeric Antigen Receptor Expression upon Drug Administration.
Sakemura R; Terakura S; Watanabe K; Julamanee J; Takagi E; Miyao K; Koyama D; Goto T; Hanajiri R; Nishida T; Murata M; Kiyoi H
Cancer Immunol Res; 2016 Aug; 4(8):658-68. PubMed ID: 27329987
[TBL] [Abstract][Full Text] [Related]
40. CAR T Cells Redirected to CD44v6 Control Tumor Growth in Lung and Ovary Adenocarcinoma Bearing Mice.
Porcellini S; Asperti C; Corna S; Cicoria E; Valtolina V; Stornaiuolo A; Valentinis B; Bordignon C; Traversari C
Front Immunol; 2020; 11():99. PubMed ID: 32117253
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]